Comparative Pharmacology
Head-to-head clinical analysis: ARISTOCORT versus PENECORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOCORT versus PENECORT.
ARISTOCORT vs PENECORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; modulates gene expression and immune cell activity.
PENECORT is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation, immune responses, and adrenal function.
Intramuscular: 40-80 mg every 2-4 weeks; Intra-articular: 5-40 mg depending on joint size; Intralesional: 2.5-25 mg; Oral: 4-12 mg/day divided every 6-12 hours.
2.5-5 mg orally once daily; maximum 10 mg/day. Intramuscular: 20-40 mg every 2-4 weeks.
None Documented
None Documented
Plasma: 1-2 hours (triamcinolone); tissue half-life 18-36 hours due to receptor binding and slow release from tissues.
Terminal elimination half-life: 3-4 hours in adults; prolonged in hepatic impairment (up to 8 hours).
Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal elimination minor.
Renal: 60-70% as metabolites, 5-10% unchanged; Biliary/fecal: 20-30% as metabolites.
Category C
Category C
Corticosteroid
Corticosteroid